A next-generation GMMA-based vaccine candidate to fight shigellosis.

Autor: Rossi O; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Citiulo F; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Giannelli C; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Cappelletti E; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Gasperini G; GSK Global Health Vaccines R&D (GVGH), Siena, Italy.; GSK Vaccines Srl, Siena, Italy., Mancini F; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Acquaviva A; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Raso MM; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Sollai L; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Alfini R; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Aruta MG; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Vitali CG; GSK Vaccines Srl, Siena, Italy., Pizza M; GSK Global Health Vaccines R&D (GVGH), Siena, Italy.; GSK Vaccines Srl, Siena, Italy.; Imperial College, London, United Kingdom., Necchi F; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Rappuoli R; GSK Vaccines Srl, Siena, Italy.; Fondazione Biotecnopolo, Siena, Italy., Martin LB; GSK Global Health Vaccines R&D (GVGH), Siena, Italy.; US Pharmacopoeia, Rockville, Maryland, USA., Berlanda Scorza F; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Colucci AM; GSK Global Health Vaccines R&D (GVGH), Siena, Italy., Micoli F; GSK Global Health Vaccines R&D (GVGH), Siena, Italy. francesca.x.micoli@gsk.com.
Jazyk: angličtina
Zdroj: NPJ vaccines [NPJ Vaccines] 2023 Sep 05; Vol. 8 (1), pp. 130. Date of Electronic Publication: 2023 Sep 05.
DOI: 10.1038/s41541-023-00725-8
Abstrakt: Shigellosis is a leading cause of diarrheal disease in low-middle-income countries (LMICs). Effective vaccines will help to reduce the disease burden, exacerbated by increasing antibiotic resistance, in the most susceptible population represented by young children. A challenge for a broadly protective vaccine against shigellosis is to cover the most epidemiologically relevant serotypes among >50 Shigella serotypes circulating worldwide. The GMMA platform has been proposed as an innovative delivery system for Shigella O-antigens, and we have developed a 4-component vaccine against S. sonnei, S. flexneri 1b, 2a and 3a identified among the most prevalent Shigella serotypes in LMICs. Driven by the immunogenicity results obtained in clinic with a first-generation mono-component vaccine, a new S. sonnei GMMA construct was generated and combined with three S. flexneri GMMA in a 4-component Alhydrogel formulation (altSonflex1-2-3). This formulation was highly immunogenic, with no evidence of negative antigenic interference in mice and rabbits. The vaccine induced bactericidal antibodies also against heterologous Shigella strains carrying O-antigens different from those included in the vaccine. The Monocyte Activation Test used to evaluate the potential reactogenicity of the vaccine formulation revealed no differences compared to the S. sonnei mono-component vaccine, shown to be safe in several clinical trials in adults. A GLP toxicology study in rabbits confirmed that the vaccine was well tolerated. The preclinical study results support the clinical evaluation of altSonflex1-2-3 in healthy populations, and a phase 1-2 clinical trial is currently ongoing.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: